Northwest & Ethical Investments L.P. Has $907,000 Position in STAAR Surgical (NASDAQ:STAA)

Northwest & Ethical Investments L.P. lowered its stake in STAAR Surgical (NASDAQ:STAA) by 7.0% in the fourth quarter, HoldingsChannel.com reports. The firm owned 37,339 shares of the medical instruments supplier’s stock after selling 2,828 shares during the quarter. Northwest & Ethical Investments L.P.’s holdings in STAAR Surgical were worth $907,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Quarry LP acquired a new stake in STAAR Surgical during the 3rd quarter worth $50,000. Quest Partners LLC acquired a new stake in STAAR Surgical during the 3rd quarter worth $128,000. Larson Financial Group LLC grew its holdings in STAAR Surgical by 78.3% during the 3rd quarter. Larson Financial Group LLC now owns 4,863 shares of the medical instruments supplier’s stock worth $181,000 after acquiring an additional 2,135 shares during the period. FMR LLC grew its holdings in STAAR Surgical by 79.3% during the 3rd quarter. FMR LLC now owns 7,092 shares of the medical instruments supplier’s stock worth $263,000 after acquiring an additional 3,136 shares during the period. Finally, HighTower Advisors LLC acquired a new stake in STAAR Surgical during the 3rd quarter worth $336,000. Institutional investors and hedge funds own 96.70% of the company’s stock.

STAAR Surgical Trading Down 1.1 %

STAA opened at $17.72 on Friday. The stock has a market capitalization of $874.04 million, a P/E ratio of -43.22 and a beta of 0.66. STAAR Surgical has a 12 month low of $13.50 and a 12 month high of $52.68. The firm’s fifty day simple moving average is $19.87 and its 200 day simple moving average is $25.70.

Wall Street Analysts Forecast Growth

A number of research firms have commented on STAA. StockNews.com lowered shares of STAAR Surgical from a “hold” rating to a “sell” rating in a report on Thursday, February 13th. Piper Sandler decreased their price target on shares of STAAR Surgical from $40.00 to $16.00 and set a “neutral” rating for the company in a report on Wednesday, February 12th. Stephens reissued an “equal weight” rating and issued a $17.00 price target on shares of STAAR Surgical in a report on Tuesday. Jefferies Financial Group lowered shares of STAAR Surgical from a “buy” rating to a “hold” rating in a report on Wednesday, February 12th. Finally, Stifel Nicolaus decreased their price target on shares of STAAR Surgical from $38.00 to $20.00 and set a “buy” rating for the company in a report on Wednesday, February 12th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, STAAR Surgical currently has a consensus rating of “Hold” and a consensus target price of $25.29.

Insider Activity at STAAR Surgical

In other STAAR Surgical news, major shareholder Broadwood Partners, L.P. acquired 259,616 shares of STAAR Surgical stock in a transaction dated Wednesday, February 12th. The stock was bought at an average cost of $14.96 per share, for a total transaction of $3,883,855.36. Following the purchase, the insider now directly owns 11,137,623 shares in the company, valued at approximately $166,618,840.08. This represents a 2.39 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. In the last ninety days, insiders have purchased 1,036,187 shares of company stock valued at $17,239,548. 1.00% of the stock is owned by corporate insiders.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.